Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma:: an immunohistochemical and chromogenic in situ hybridization study

被引:122
作者
Shia, J
Klimstra, DS
Li, AR
Qin, J
Saltz, L
Teruya-Feldstein, J
Akram, M
Chung, KY
Yao, D
Paty, PB
Gerald, W
Chen, BY
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[2] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
关键词
cetuximab; anti-EGFR therapy; gene amplification;
D O I
10.1038/modpathol.3800417
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Recent data suggest that detection of epidermal growth factor receptor protein by immunohistochemistry ( IHC) does not predict response to the antiepidermal growth factor receptor drug, cetuximab, in patients with colorectal carcinoma. In searching for foundation for further investigation to optimize patient selection for cetuximab therapy, this study sought to exploit the tissue microarray and chromogenic in situ hybridization techniques to evaluate the status of epidermal growth factor receptor gene amplification in colorectal cancer and its relationship with protein expression by IHC. The study included 158 primary or metastatic colorectal adenocarcinomas. Immunohistochemical results were scored as 0 - 3 + based on the intensity of membrane staining. The in situ hybridization signals were counted in 30 nuclei per tissue core. Overall, the rate of tissue loss was 7%, yielding 147 analyzable cases: 123 primary, 24 metastatic. Positive immunohistochemical staining of any intensity was detected in 85% ( 105/ 123) of primary and 79% ( 19/ 24) of metastatic tumors, whereas gene amplification ( 45 gene copies/ nucleus) was only seen in 12% ( 15/ 123) of primary and 8% ( 2/ 24) of metastatic tumors. Only 2/ 15 primary and 1/ 2 metastatic tumors that showed gene amplification were amplified at a high level ( 410 gene copies/ nucleus). Although a positive correlation was detected between the intensity of protein expression and the likelihood of gene amplification in both the primary ( P = 0.01) and the metastatic ( P = 0.05) tumors, IHC had a low specificity ( 17% in primary, 23% in metastatic) in predicting gene amplification. Conversely, all tumors that did not express the protein by IHC lacked gene amplification. Thus, this study shows that only a small fraction of epidermal growth factor receptor- positive colorectal carcinomas detected by IHC are associated with gene amplification. Additional studies are needed to determine whether epidermal growth factor receptor gene amplification bears any informative value in predicting response to cetuximabbased therapy.
引用
收藏
页码:1350 / 1356
页数:7
相关论文
共 36 条
[1]   Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues:: Variation in staining intensity due to choice of fixative and storage time of tissue sections [J].
Atkins, D ;
Reiffen, KA ;
Tegtmeier, CL ;
Winther, H ;
Bonato, MS ;
Störkel, S .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2004, 52 (07) :893-901
[2]  
Baselga J, 2001, EUR J CANCER, V37, pS16
[3]   Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma [J].
Bhargava, R ;
Lal, P ;
Chen, BY .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2004, 13 (04) :213-216
[4]   Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification -: Does it measure up to fluorescence in situ hybridization? [J].
Bhargava, R ;
Lal, P ;
Chen, BY .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (02) :237-243
[5]   Validation of tissue microarray technology in breast carcinoma [J].
Camp, RL ;
Charette, LA ;
Rimm, DL .
LABORATORY INVESTIGATION, 2000, 80 (12) :1943-1949
[6]   Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].
Chung, KY ;
Shia, J ;
Kemeny, NE ;
Shah, M ;
Schwartz, GK ;
Tse, A ;
Hamilton, A ;
Pan, D ;
Schrag, D ;
Schwartz, L ;
Klimstra, DS ;
Fridman, D ;
Kelsen, DP ;
Saltz, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810
[7]  
Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
[8]   Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs [J].
Ciardiello, F ;
Tortora, G .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (10) :1348-1354
[9]  
Ciardiello F, 1999, CLIN CANCER RES, V5, P909
[10]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345